Repligen Corporation (RGEN)

176.25
NASDAQ
Prev Close 176.51
Day Low/High 173.01 / 177.92
52 Wk Low/High 76.75 / 177.29
Exchange NASDAQ
Shares Outstanding 52.50B
Market Cap 9.27B
P/E Ratio 304.33
Div & Yield N.A. (N.A)

Latest News

Trump's Health and the Market, Charts That Matter, Nvidia News, URI Breaks Out

Trump's Health and the Market, Charts That Matter, Nvidia News, URI Breaks Out

Even more important than fiscal support moving forward would be the concept of Covid-19 very soon being effectively treatable for the public.

Markets in Limbo, Stimulus Needed, Virus in Charge, Presidential Politics

Markets in Limbo, Stimulus Needed, Virus in Charge, Presidential Politics

The short-term story for financial markets has been all about fiscal policy. This remains true.

Jim Cramer: What Does the Stock Market Forecast for the Economy?

Jim Cramer: What Does the Stock Market Forecast for the Economy?

The stock market is out of sync with the current economy, but it can be a forecasting machine. Let's see what it says.

3 Biotech Stocks With the Best-Looking Charts

3 Biotech Stocks With the Best-Looking Charts

Biotech is on fire right now, but these 3 stocks 'sleeper' stocks aren't yet overbought.

Biotech and Beyond: 8 Favorite Healthcare Stocks for 2019

Biotech and Beyond: 8 Favorite Healthcare Stocks for 2019

From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.

Drug Stocks Find Trump Animus a Bitter Pill

Drug Stocks Find Trump Animus a Bitter Pill

The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.

5 Health Care Stocks Set to Bounce

5 Health Care Stocks Set to Bounce

These stocks are down some 20% over the last 30 months and look ripe for a rise.

Repligen Has More Upside Ahead

Repligen Has More Upside Ahead

Add to longs on a short-term correction.

Where the Money Was Made the Last 5 Years

Where the Money Was Made the Last 5 Years

Only one fund category (of 20) has beaten the S&P 500 over half a decade.

The Trader Daily

The Trader Daily

Don't batten down the hatches yet.

Some Weekend Folding Money

Some Weekend Folding Money

I'm content to head into the weekend with my short-term book mostly on the cash side.

Biotech Breakouts

Biotech Breakouts

Favorable charts for Celldex, Repligen and Arrowhead Research.